VCT220 PK Interactions in Healthy, Overweight, and Obese Subjects

Phase 1, open-label, single-arm trial of VCT220 in obesity, sponsored by Vincentage Pharma Co., Ltd. Primary endpoints: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration of Repaglinide at 24 hours, Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration of Rosuvastatin at 120 hours and 4 more. Started Jul 2025; status: completed.